Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance by unknown
RESEARCH Open Access
Regional myocardial microvascular
dysfunction in cardiac amyloid light-chain
amyloidosis: assessment with 3T
cardiovascular magnetic resonance
Rui Li1,4, Zhi-gang Yang1,2*†, Lin-yi Wen1, Xi Liu1, Hua-yan Xu1,2, Qin Zhang1 and Ying-kun Guo3*†
Abstract
Background: Coronary microvascular dysfunction is highly prevalent in patients with amyloid light-chain (AL)
cardiac amyloidosis (AL-CA). The aim of this study was to clarify the feasibility of first-pass perfusion imaging using
3 T cardiovascular magnetic resonance (CMR) for evaluating the difference in left ventricular (LV) regional myocardial
microvascular function among normal subjects and in patients with AL-CA. The amyloidosis patients were classified
into those with impaired systolic function [LV ejection fraction (LVEF) < 50 %] and those with preserved systolic
function.
Methods: In total, 32 patients with biopsy-proven AL-CA, including 11 AL-CA patients with systolic dysfunction,
21 AL-CA patients with preserved systolic function, and 25 healthy subjects, underwent CMR examination. LV
regional myocardial perfusion parameters included upslope, time to maximum signal intensity (TTM) and max
signal intensity (MaxSI) were compared among the three patient groups. Receiver operating characteristic
analysis was performed to determine whether perfusion parameters could be used in discriminating regional
myocardial microvascularity between AL-CA patients and normal subjects.
Results: The patients with AL-CA had significantly reduced first-pass perfusion upslope and MaxSI, and increased TTM
compared with the normal subjects (all P < 0.01). Compared with the patients with AL-CA and preserved LVEF,
the patients with AL-CA and impaired systolic function had a longer TTM in the basal (47.05 ± 16.59 vs. 39.68 ±
19.11; P = 0.002) and mid-ventricular (44.61 ± 16.34 vs. 37.74 ± 18.25; P = 0.002) segments; lower upslope in the
basal (2.41 ± 1.32 vs. 3.60 ± 1.68; P < 0.0001), mid-ventricular (2.82 ± 1.34 vs. 4.15 ± 2.02; P < 0.0001), and apical
(3.71 ± 1.38 vs. 4.97 ± 2.55; P = 0.004) segments; and lower MaxSI (31.67 ± 15.23 vs. 37.96 ± 11.15; P < 0.0001) in
the basal segment. The ROC curve analysis revealed that the first-pass upslope, TTM, and MaxSI may be used as
indicators for differentiating microcirculation between AL-CA patients with preserved or impaired systolic
function and normal subjects.
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Conclusions: The differences in LV regional myocardial microvascular function among normal subjects, AL-CA
patients with systolic dysfunction, and AL-CA patients with preserved systolic function can be monitored using
first-pass perfusion CMR.
Keywords: Amyloid light-chain cardiac amyloidosis, Cardiovascular magnetic resonance, Perfusion imaging,
Left ventricular function, Coronary microvascular function
Background
Amyloidosis is a rare disorder characterized by the
extracellular deposition of pathological insoluble pro-
teins in multiple organs, including the heart [1, 2].
Amyloid light-chain (AL) amyloidosis, in which amyloid
fibrils are derived from the monoclonal immunoglobulin
light chain, is one the most common types of amyloid-
osis [3]. Cardiac involvement, termed cardiac amyloid-
osis (CA), is observed in approximately 50 % patients
with systemic amyloidosis and is also the major cause of
death in patients with AL amyloidosis [4, 5]. AL-CA has
a poor prognosis, particularly in patients with impaired
systolic function and abnormal wall thickening. The left
ventricular ejection fraction (LVEF), which is widely used
as an index of systolic function in clinical practice, is
considered an independent predictor of cardiac mortality
in AL amyloidosis [3, 4].
Necroscopy examinations have confirmed that amyloid
infiltration in the microvascular system may cause cor-
onary microcirculation disorder, with patients presenting
with symptoms of angina and signs of ischemia [6–8]. In
addition, increased wall thickness, an important mor-
phologic feature of CA, may affect myocardial micro-
vascular perfusion due to vascular rarefaction and
compression [9].
As amyloid infiltration in the cardiac microvascular sys-
tem is prevalent in patients with CA and is potentially asso-
ciated with LV systolic function and wall thickening [3, 9],
it is essential to evaluate coronary microvascular perfusion
in patients with AL-CA, particularly in those with systolic
dysfunction. Clinically, contrast-enhanced cardiovascular
magnetic resonance (CE-CMR) is regarded as a well-
established method for the assessment of cardiac morph-
ology, function, and tissue characteristics [10, 11]. High
field 3 T CMR improves the signal to noise ratio, contrast
to noise ratio, and first-pass myocardial perfusion CMR
[12, 13]. Higher levels of accuracy, sensitivity, specificity
and reproducibility can be achieved by using CMR perfu-
sion parameters, including slope, TTM, and MaxSI [12, 14,
15]. These parameters, derived from the CMR signal
intensity-time curve and reflected myocardial perfusion re-
serve, are associated with coronary microvascular function
[16]. By using a first-pass myocardial perfusion technique,
CMR can be used to monitor myocardial microvascular
dysfunction in hypertrophic and dilated cardiomyopathy in
a non-invasive manner [17, 18]. Additional, CE-CMR im-
aging allows the simultaneous assessment of both myocar-
dial perfusion and function in a single investigation.
However, to the best of our knowledge, few studies have in-
vestigated myocardial microvascular dysfunction in patients
with AL-CA using CMR. Thus, the aim of this study was to
assess regional myocardial perfusion and function in AL-
CA patients using 3.0-T CE-CMR imaging and to deter-
mine whether these perfusion parameters may assist in
discriminating between the microcirculation of AL-CA




The institutional ethics committee of our hospital ap-
proved this study, and written informed consent was
obtained from each participant prior to the investiga-
tion. Between September 2013 and March 2015, 38 pa-
tients with biopsy-proven AL amyloidosis were
enrolled in the study, according to the following inclu-
sion criteria: (a) AL amyloidosis, initially diagnosed in
extracardiac tissue using congo red and immunohisto-
chemical staining and (b) cardiac involvement, con-
firmed according to echocardiographic criteria [19].
The exclusion criteria included (a) associated diseases
that may cause myocardium hypertrophy and/or cor-
onary mircovascular dysfunction, such as hypertrophic
cardiomyopathy, diabetes, hypertension, coronary ar-
tery disease, and arrhythmia and (b) non-interpretable
MR image quality, unsuitable to enable diagnosis. In
total, 32 AL-CA patients remained following the exclu-
sion of six patients who met the aforementioned exclu-
sion criteria. The mean patient age was 60 years
(range, 38–75 years). In total, 15 of the 32 patients
(47 %) were women. During the same period, 25 nor-
mal controls (13 males and 12 females; mean age,
37.68 ± 11.94 years; range, 17–58 years) underwent
CMR on initial clinical suspicion of cardiovascular dis-
ease but were confirmed as healthy subjects by clinical
evidence and served as a control group. The exclusion
criteria included chronic disease, family history of car-
diovascular disease, diabetes, hypertension (>140/
90 mmHg), and arrhythmia. Prior to CMR, routine
clinical echocardiography was performed in all subjects
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using two-dimensional transthoracic echocardiography
(TEE) with a multiplanar 3.5-MHz probe (IE33; Philips
Medical Systems, Andover, MA, USA), according to
the guidelines of the American Society of Echocardiography
[20]. Endomyocardial biopsy was not performed in our
study due to its invasive nature and the severity of its po-
tential complications [21]. Thus, the patients were diag-
nosed with CA via extracardiac tissue biopsy, which was
obtained through specimens of kidney (n = 6; 18.8 %), bone
marrow (n = 27; 84.4 %), liver (n = 1; 3.1 %), fat (n = 6;
37.5 %), rectum (n = 1; 3.1 %), skin (n = 5; 15.6 %), and
tongue (n = 1; 3.1 %) and typical echocardiographic find-
ings, including a mean wall thickness of the ventricular wall
and/or interventricular septum measuring >12 mm in
diastole [19].
CMR
All patients were examined in the supine position using
a 3 T whole-body scanner (Trio Tim; Siemens Medical
Solutions, Erlangen, Germany) at least 3 days following
ECG examination. A dedicated two-element cardiac-
phased array coil was used for signal detection. The
manufacturer’s standard ECG-triggering device and the
breath-hold technique were used to monitor the individ-
uals’ ECG values and breathing, respectively. Following a
survey scan, cine images were acquired in 2-chamber, 3-
chamber, and 4-chamber views using a TrueFISP se-
quence (TR/TE, 44.7/1.33 ms; flip angle, 50°; field of
view, 290 mm× 373 mm; matrix size 146 mm× 224 mm;
slice thickness, 8 mm). Subsequently, gadobenate dime-
glumine (MultiHance; 0.5 mmol/ml; Bracco, Milan,
Italy) was intravenously injected using an automated in-
jector (Stellant, MEDRAD, Indianola, PA, USA) at a
dose of 0.1 ml/kg body weight and a flow rate of 2.5–
3.0 ml/s. In addition, a 20 ml saline flush was injected
immediately following contrast at a rate of 3.0 ml/s. Rest
regional perfusion images were acquired in three stand-
ard short-axis slices (apical, middle, and basal) and in
one slice of the 4-chamber view using an inversion-
recovery prepared echo-planar imaging sequence (repeti-
tion time, 200 ms; echo time, 1.1 ms; inversion time,
90.0 ms; flip angle, 10°; field of view, 270 mm × 360 mm;
acquisition matrix, 106 × 192; slice thickness, 8 mm).
Each set of first-pass perfusion images was completed in
80 cardiac cycles.
CMR data analysis
Image analysis was performed offline using commercial
software (cvi42; Circle Cardiovascular Imaging, Inc.,
Calgary, Canada). Endocardial and epicardial traces were
performed manually by two experienced observers (Wen
LY and Li R) in the serial short-axis slices at the end-
diastolic and end-systolic phases. The global cardiac
function, including LV end-diastolic volume (EDV), end-
systolic volume (ESV), and LV ejection fraction (LVEF)
were computed using a modified Simpson’s rule. For re-
gional analysis, a 16-segment mode (Bull’s eye plot),
according to AHA standard segmentation, was con-
structed on the basis of analysis of the long- and short-
axis slices (apical, mid-ventricular, and basal; Fig. 1),
which included four apical segments (septum, anterior,
lateral, and inferior), and six mid-ventricular and basal
segments (inferior septum, anterior septum, anterior, an-
terolateral, inferolateral, and inferior). Morphologically,
the average LV end-diastolic and -systolic wall thickness
for each segments were measured, and the myocardial
wall thickening, defined as the variation in thickness be-
tween diastole to systole, expressed as a percentage
(Wth) were calculated using the centerline method [22].
For evaluation of the LV regional perfusion, the endocar-
dial, epicardial, and blood pool contours of all three sets
of first-pass perfusion images (basal, mid-ventricular,
Fig. 1 AHA bull’s eye model according to standard segmentation for regional analysis. Based on this model, segmentation of the LV on
myocardial first-pass perfusion images included the following: (a) Basal segments; (b) Mid-ventricular segments; and (c) Apex segments. LV wall
end-diastolic thickness was also determined using this model
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and apical) were delineated manually, and the myocar-
dial signal intensity-time curve was processed using
the aforementioned software. First-pass parameters in-
cluding upslope, time to maximum signal intensity
(TTM) and max signal intensity (MaxSI) were conse-
quently obtained from the myocardial signal intensity-
time curve (Fig. 2).
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware (version 19.0 for Windows; SPSS, Chicago, IL,
USA). The results are expressed as the mean ± standard
deviation (SD). Continuous variables were compared
using independent Student’s t-test or one-way analysis of
variance (ANOVA). A Mann–Whitney U test was used
to compare the regional myocardial perfusion and func-
tional parameters among the normal subjects and the
AL-CA patients with or without systolic dysfunction
using Bonferroni’s correction for multi-group compari-
sons. If a significant difference was confirmed, receiver
operating characteristic (ROC) analysis was performed
to determine whether the cut-off values of regional car-
diac perfusion can be used to differentiate myocardial
microvascular function between AL-CA patients and
normal subjects. Spearman’s rank correlations analysis
was performed to examine the correlation between re-
gional myocardial perfusion, wall thickness, and wall




The baseline characteristics the AL-CA patients and
normal subjects are presented in Table 1. Of the 32
cardiac patients, 11 (34.4 %) presented with impaired
systolic function (LVEF < 50 %). Half of the AL-CA
patients had a history of New York Heart Association
functional class ≥ III heart failure. The LVEDV of the
AL-CA patients with preserved LVEF was lower than
that of the normal healthy controls (P = 0.013). The AL-
CA patients with impaired LVEF had a significantly
higher LVESV and lower SV than that of the normal
subjects and the AL-CA patients with preserved LVEF
(all P < 0.001). However, no statistically significant differ-
ences were observed between the patients with pre-
served LVEF and the normal subjects in LVESV (47.45 ±
12.97 vs. 52.62 ± 14.01 ml; P = 0.693) or LVEF (56.62 ±
9.43 vs. 60.18 ± 4.30 %; P = 0.059). The LV mass in the
AL-CA patients were markedly increased as compared
with that in the normal subjects (both P < 0.0001); how-
ever, there was no significant difference between the AL-
CA patients with LV systolic dysfunction and those
without LV systolic dysfunction (143.55 ± 42.64 vs.
127.14 ± 32.29 g; P = 0.484). After CMR and echocardi-
ography, fifteen (46.9 %) patients received chemotherapy
whereas seventeen (53.1 %) did not, and the chemother-
apy regimen was listed in Table 2.
LV wall functional analysis
The AL-CA patients had significantly thicker EDWT
and ESWT and reduced Wth compared with the nor-
mal controls (all P < 0.05; Table 3). Compared with the
AL-CA patients with preserved LVEF, the AL-CA
patients with LV systolic dysfunction presented with re-
duced Wth (P < 0.0001) and increased EDWT (P = 0.014).
However, there was no significant difference in ESWT
between the AL-CA patients with LV systolic dysfunc-
tion and those without LV systolic dysfunction. Using
Fig. 2 The signal intensity-time curve derived from myocardial perfusion images. The first-pass perfusion values including MaxSI (a), time to max
signal intensity (b) and first-pass perfusion upslope (c) were automatically obtained
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the Bull’s eye plot, baso-apical gradients of decreased
EDWT and ESWT and increased Wth were observed
in the AL-CA patients. The average differences in
EDWT, ESWT, and Wth in the basal, mid-ventricular,
and apical segments between the AL-CA patients with
or without LV systolic dysfunction were compared
(Table 4). The AL-CA patients with LV systolic
dysfunction presented with lower Wth in the basal and
mid-ventricular segments as compared with the AL-CA pa-
tients with preserved LVEF (27.70 ± 23.11 vs. 48.91 ± 39.54;
P = 0.001 and 65.00 ± 44.18 vs. 86.30 ± 52.67; P = 0.007, re-
spectively) and thicker EDWT in the basal segment (13.90
± 3.11 vs. 12.85 ± 3.76; P = 0.02). However, no significant
differences in ESWT were observed between the AL-
CA patients with or without LV systolic dysfunction in
any of the three segments.
Table 1 Baseline Differences Between Cardiac Normal healthy, AL-CA patients with or without LV systolic dysfunction
Normal subjects (n = 25) CA without SD (n = 21) CA with SD (n = 11)
Age (Y) 37.68 ± 11.94 60.10 ± 7.85* 59.82 ± 12.14*
Male 13 (52) 11 (52) 6 (55)
NYHA functional class
I - 2 (9) 0 (0)
II - 10 (48) 4 (36)
III - 9 (43) 5 (46)
IV - 0 (0) 2 (18)
Echocardiography
Septal thickness (mm) 8.73 ± 1.55 15.29 ± 2.83* 17.27 ± 2.57*
E/A 1.2 ± 0.2 1.7 ± 0.6* 2.4 ± 0.8*§
E/E’ 11.11 ± 2.21 17.14 ± 4.33* 20.82 ± 5.69*§
Cine-CMR
LVEDV (ml) 133.78 ± 25.43 111.06 ± 26.84* 118. 20 ± 24.47
LVESV (ml) 52.62 ± 14.01 47.45 ± 12.97 71.95 ± 17.71*§
LV SV (ml) 81.18 ± 15.29 63.60 ± 23.44* 46.25 ± 10.78*§
LVEF (%) 60.18 ± 4.30 56.62 ± 9.43 39.28 ± 6.39*§
LV mass (g) 85.32 ± 23.32 127.14 ± 32.29* 143.55 ± 42.64*
Pericardial effusion - 12 (57) 4 (36)
Pleural effusion - 13 (67) 7 (63)
Notes: The values are the mean ± SD, Numbers in the brackets are percentages. *P < 0.017 versus normal group; §P < 0.0017 versus CA with preserved LVEF.
AL-CA = light-chain amyloid cardiac amyloidosis; SD = systolic dysfunction; LV = left ventricular; EDV = end diastolic volume; ESV = end systolic volume; EF = ejection
fraction; SV = stroke volume
Table 2 Chemotherapeutic agents used
Chemotherapy regimen No. of
subjects
Cyclophosphamide, thalidomide, dexamethasone 4
Cyclophosphamide, thalidomide, dexamethasone/prednisone 1

















Upslope 6.64 ± 2.03 4.15 ± 2.11* 2.89 ± 1.43*§
TTM (sec) 20.35 ± 13.74 39.00 ± 18.60* 45.81 ± 16.25*§
MaxSI 52.74 ± 12.10 42.08 ± 12.79* 38.21 ± 18.34*§
EDWT (mm) 6.92 ± 1.99 10.28 ± 3.87* 11.06 ± 3.72*§
ESWT(mm) 12.71 ± 3.51 16.74 ± 3.59* 16.29 ± 3.91*
Wth(%) 93.18 ± 62.07 77.97 ± 53.05* 58.64 ± 50.59*§
Notes: The values are the mean± SD, *P< 0.017 versus normal group; §P< 0.017
versus CA without systolic function; SD = systolic dysfunction; TTM= time to max;
EDWT= end-diastole wall thickness; ESWT= end-systole wall thickness;
Wth =wall thickening
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Table 4 Regional comparison of first perfusion and function parameters between AL-CA subject with or without LV systolic dysfunction
Basal Mid-ventricular apex
Normal CA without SD CA with SD Normal CA without SD CA with SD Normal CA without SD CA with SD
Upslope 6.52 ± 1.85 3.60 ± 1.68* 2.41 ± 1.32*§ 6.57 ± 2.07 4.15 ± 2.02* 2.82 ± 1.34*§ 6.95 ± 2.22 4.97 ± 2.55* 3.71 ± 1.38*§
TTM (sec) 19.51 ± 9.68 39.68 ± 19.11* 47.05 ± 16.59*§ 19.78 ± 16.94 37.74 ± 18.25* 44.61 ± 16.34*§ 22.47 ± 13.47 39.88 ± 18.46* 45.75 ± 15.83*
MaxSI 51.17 ± 10.86 37.96 ± 11.15* 31.67 ± 15.23*§ 52.96 ± 12.20 41.61 ± 12.18* 38.07 ± 18.24* 53.96 ± 13.62 48.95 ± 13.24* 48.21 ± 18.63*
EDWT (mm) 8.36 ± 1.88 12.85 ± 3.76* 13.90 ± 3.11* 6.71 ± 1.44 9.82 ± 3.08* 10.41 ± 3.02* 5.08 ± 1.00 7.09 ± 2.04* 7.77 ± 1.96*
ESWT (mm) 13.86 ± 3.99 18.00 ± 3.03* 17.43 ± 3.81* 12.86 ± 2.80 17.14 ± 3.40* 16.39 ± 3.97* 10.75 ± 2.84 14.27 ± 3.45* 14.44 ± 3.29*
Wth(%) 72.14 ± 59.86 48.91 ± 39.54* 27.70 ± 23.11*§ 97.47 ± 53.27 86.30 ± 52.67 65.00 ± 44.18*§ 118.29 ± 67.79 109.06 ± 49.61 95.51 ± 61.16*












First pass perfusion analysis
The first-pass perfusion parameters of all subjects are
shown in Table 3. Using the Bull’s eye mode with re-
gional wall functional analysis, the average first perfusion
parameters of the basal, mid-ventricular, and apical seg-
ments were calculated (Table 4). Gradual increases in
upslope and MaxSI, from base to apex, were observed in
the AL-CA patients, regardless of LVEF. Compared with
the normal controls, the upslope and MaxSI of the AL-
CA patients were significantly reduced, and the TTM
was significantly increased (all P < 0.01). The AL-CA
patients with LV systolic dysfunction exhibited a shorter
upslope in the three segments (all P < 0.01), reduced
MaxSI in the basal segment, and longer TTM in the
basal and mid-ventricular segments (all P < 0.01) as com-
pared with the AL-CA patients without LV systolic
dysfunction.
Correlation between regional first-perfusion, wall
thickness, and wall thickening
A significant and positive correlation was demonstrated
between the first-pass upslope and Wth (Spearman’s
rank = 0.258; P < 0.0001) and between the MaxSI and
Wth (Spearman’s rank = 0.338; P < 0.0001). A negative
correlation was found between the first-pass perfusion
upslope and EDWT (Spearman’s rank = −0.431; P < 0.0001)
and ESWT (Spearman’s rank = −0.355; P < 0.0001) and
between the MaxSI and EDWT (Spearman’s rank = −0.458;
P < 0.0001) and ESWT (Spearman’s rank = −0.288;
P < 0.0001).
ROC curve analysis
Following ROC analysis in the basal, mid-ventricular,
and apical segments, we found that the cut-off values for
the first-pass upslope, TTM, and MaxSI assisted in dis-
criminating between the microvascularity of AL-CA pa-
tients with preserved or impaired LVEF and normal
controls (Figs. 3 and 4). The area under the ROC curve,
and the sensitivity and specificity of the LV regional first
by-pass perfusion data used for the discrimination re-
gional myocardial microvascularity between AL-CA pa-
tients with or without LV systolic dysfunction and
normal controls are summarized in Tables 5 and 6.
Discussion
In this study, we assessed the use of 3 T CMR to provide
information on regional myocardial microcirculation
and wall abnormalities in AL-CA patients. We found
that the TTM, EDWT, and ESWT were increased and
the first-pass perfusion slope, MaxSI, and Wth were de-
creased significantly in the AL-CA patients compared
with the normal controls. Furthermore, coronary micro-
vascular dysfunction was significantly correlated with LV
wall thickness and wall thickening, which is consistent
with a previous report [9]. These findings suggested that
myocardial perfusion in AL-CA patients is poorer than
that in healthy individuals due to coronary microcircula-
tion disorder. The increased wall thickness and abnor-
mal wall thickening may also contribute to myocardial
perfusion dysfunction.
Coronary microvascular dysfunction is common in pa-
tients with AL amyloidosis. Symptoms of angina and is-
chemia, impaired vasodilatation, and minimal coronary
vascular resistance have been described in CA patients
without coronary artery disease [9, 23–25]. The amyloid
deposition leading to coronary microvascular dysfunc-
tion in CA patients may be sustained by several patho-
genetic mechanisms, including structural (amyloid
infiltrated the vascular wall causing wall thickening and
luminal obstruction), functional (autonomic and endo-
thelial) and extravascular (perivascular and interstitial
amyloid deposits leading to extramural compression and
decreased diastolic perfusion time) [9, 26]. In addition,
the mechanisms of coronary microvascular dysfunction
Fig. 3 Receiver-operating characteristic analysis (ROC) between AL-CA patients with preserved LV systolic function and normal controls. By using
the cut-off values of upslope (Green), TTM (Blue) and MaxSI (Red), the first-pass perfusion MR could discriminate the myocardial microvascularity
of AL-CA patients with preserved LV systolic function from that of normal controls in the basal (a), mid-ventricular (b) and apex (c) segments
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in other non-ischemic cardiomyopathies, including
small-vessel vasculitides, coronary microvascular remod-
eling, interstitial fibrosis, increased LV end-diastolic
pressures and LV myocardial mass, and decreased capil-
lary density may assist in explaining coronary microcir-
culation disorder in CA [27, 28].
A gradient of basoapically decreasing/increasing slope,
MaxSI, and Wth gradient were also observed in the AL-
CA patients. This basoapical gradient also reflecting
underlying myocardial wall stress in the left ventricle,
are in accordance with other CMR findings which
showed greater Late Gadolinium Enhancement (LGE)
area at the base compared with the apex segments, and
echocardiographic studies using strain analysis, which
reported reduced basal systolic longitudinal and radial
strain in CA [29–32].
Another finding in our study was that the AL-CA pa-
tients with impaired LVEF were associated with more
marked regional LV microvascular disorder as compared
with the AL-CA patients with preserved LVEF. As an in-
dependent predictor of cardiac mortality in AL amyloid-
osis patients, systolic dysfunction tends to occur in
advanced stages of the disease and is often associated
with poor outcome [4, 33, 34]. AL-CA patients with im-
pairment of systolic function have been considered in-
appropriate for autologous stem cell transplantation,
which is generally accepted as a therapeutic approach to
improve the survival rates and quality of life in AL amyl-
oidosis [35–37]. Thus, early identification of the systolic
function in AL-CA patients may assist obtaining pre-
therapeutic information and improve prognosis.
Sharmila et al. indicated that the longitudinal strain,
reflecting subclinical LV systolic function, is often re-
duced in CA patients as compared with hypertensive LV
hypertrophy, suggesting that the longitudinal dysfunc-
tion is linearly associated with microvascular impairment
Table 5 ROC analysis of first-pass perfusion for detecting microvascular dysfunction between AL-CA patients with preserved systolic
function and normal controls
Cutoff AUC Sensitivity (%) (95 % CI) Specificity (%) (95 % CI)
Basal segment
Upslope 5 0.888 87 (82–93) 81 (74–87)
TTM 20.8 0.843 79 (70–85) 73 (66–80)
MaxSI 42 0.816 68 (59–76) 85 (78–90)
Mid-ventricular segment
Upslope 4 0.794 58 (49–67) 90 (84–94)
TTM 19.9 0.848 85 (78–91) 67 (59–75)
MaxSI 42 0.741 58 (49–67) 82 (75–88)
Apical segment
Upslope 4 0.747 52 (41–63) 94(87–98)
TTM 21.87 0.795 77 (67–86) 70 (60–79)
MaxSI 41 0.610 37 (27–48) 86 (78–92)
Notes: AUC = area under the ROC curve. The abbreviations are the same as in Tables 1 and 2
Fig. 4 Receiver-operating characteristic (ROC) analysis between AL-CA patients with impaired LV systolic function and normal controls. The use of
cut-off values of upslope (Green), TTM (Blue) and MaxSI (Red) could discriminate the microcirculation of AL-CA patients with impaired LV systolic
function from that of normal controls in the basal (a), mid-ventricular (b) and apex (c) segments
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[9]. Taken together, we hypothesized that coronary
microvascular dysfunction is involved in LV systolic im-
pairment and that the evaluation of regional myocardial
microcirculation in AL-CA patients may facilitate the
early identification of the regional impairment of systolic
function.
As significant differences in first by-pass perfusion pa-
rameters were observed between the AL-CA patients
with impaired or preserved systolic function and the
normal controls, these perfusion data may assist in dis-
criminating between the microvascular dysfunction AL-
CA patients and normal controls. The data obtained
from the ROC analysis supported the use of the upslope,
TTM, and MaxSI as criteria to enable the differentiation
of the microcirculation of AL-CA patients, regardless of
LVEF, from that of normal control individuals. Besides,
precise identification of amyloisosis type is also crucial
in clinical setting due to the prognosis and the treatment
depends on the type of this disease. CMR LGE could
help differentiate noninvasively between cardiac light
chain amyloid and transthyretin-related amyloidosis
(ATTR), and among different ATTR pathogenic muta-
tion groups [29, 38]. As previously research reported,
coronary microvascular dysfunction is highly prevalent
in cardiac amyloidosis patients regardless of the under-
lying type of amyloid deposits [9], however, the precise
clinical utility of our findings are not clear. Further study
is require to determine if myocardial perfusion param-
eter could help classify the type of cardiac amyloidosis,
and may subsequently be an early clinical makers for
screening and identification asymptomatic relatives for
phenotypic heterogeneity in hereditary ATTR amyloid.
In addition, the process of successful treatment of AL
amyloidosis aiming to eliminate or control the dyscrasia
that produces the amyloid paraprotein and reflecting by
a decrease in cardiac biomarkers, may prior to a change
in typical morphologic appearances, and whether coron-
ary microvascular function also response to chemother-
apy needs further investigation.
Our study had several limitations. Firstly, a larger sam-
ple size of AL-CA patients is required for further investi-
gation, with an emphasis on myocardial perfusion.
Secondly, our present study did not evaluate whether
the interstitial myocardial fibrosis detected by LGE or
quantified by T1 blood-pool gadolinium kinetics or T1
mapping on CMR could affect coronary microvascular
dysfunction, which are valuable for differential diagnosis
and the prediction of outcomes in CA patients [39–41].
The association between LGE, and T1 blood-pool gado-
linium kinetics or T1 mapping, and first-perfusion im-
aging on CMR in CA patients will be investigated in our
future study. Thirdly, resting/exercise electrocardiogram,
echocardiography and laboratory examination was per-
formed to exclude coronary heart disease, however, not
all AL-CA subjects received coronary angiography in
our study, which could help to scientifically prove that
ischemia is caused by microvascular dysfunction. Finally,
patients with LVEF < 50 % were defined as exhibiting im-
paired systolic function in our study. However, LVEF re-
flects the global LV systolic function and is less sensitive
in assessing the regional systolic function. In addition,
CA patients has smaller cavity sizes (reduced LVEDV)
due to increased wall thickness could result in a com-
parative decrease in EF compared with normal controls,
EF may be >50 % in patients with small cavity size result
from concentric “hypertrophy”, thus may not accurate to
evaluated the systolic function and may consequently
mis-classifying some patients with truly impaired systolic
function into the normal systolic function group. Dan
Liu et al. previously reported that longitudinal
Table 6 ROC analysis of first-pass perfusion for detecting microvascular dysfunction between AL-CA patients with impaired systolic
function and normal controls
Cutoff AUC Sensitivity (%) (95 % CI) Specificity (%) (95 % CI)
Basal segment
Upslope 4.1 0.969 92 (83–98) 93 (88–97)
TTM 21.9 0.932 97 (90–100) 76 (68–83)
MaxSI 42 0.852 79 (67–88) 85 (78–90)
Mid-ventricular segment
Upslope 4 0.941 89 (79–96) 90 (84–94)
TTM 21.68 0.941 98 (92–100) 77 (69–83)
MaxSI 36 0.772 61 (48–72) 94 (89–97)
Apical segment
Upslope 4.57 0.906 77(62–88) 94 (87–98)
TTM 23 0.886 95 (85–99) 74 (64–82)
MaxSI 43 0.638 52 (37–68) 77 (68–85)
Notes: AUC = area under the ROC curve. The abbreviations are the same as in Tables 1 and 2
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dysfunction was associated with poor outcome in CA
patients with preserved LVEF [42]. Therefore, the associ-
ation between first-pass data and more sensitive indices
reflecting the LV systolic function, including strain and
pulsed tissue Doppler echocardiography, which can as-
sist in the early identification of systolic dysfunction, will
be discussed in our future study.
Conclusions
The difference of LV regional myocardial microvascular
function among AL-CA patients with or without LV sys-
tolic dysfunction, and normal subjects can be monitored
by first-pass perfusion CMR imaging, and the threshold
values of LV regional myocardial perfusion parameters
may be used as indicators for differentiating myocardial
microvascular dysfunction between AL-CA patients with
preserved or impaired systolic function and normal
subjects.
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